Cord Blood-derived Expanded Allogeneic Natural Killer Cells (MD Anderson Cancer Center)

N/A

Report date: 2022/12/25 12:12:05

Base Information

Drug NameCord Blood-derived Expanded Allogeneic Natural Killer Cells (MD Anderson Cancer Center)
Drug Alias NameAllogeneic CB-derived Ex vivo-expanded NK CellsCB-derived Expanded Allogeneic NK CellsUCB-derived Expanded Allogeneic NK CellsUmbilical Cord Blood-derived Expanded Allogeneic Natural Killer Cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsGliosarcomaLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsGliosarcomaLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A